MedTrace Logo

fMRI Study Examining Effects of D-cycloserine in Specific Phobia

NCT00591825 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2017-06-05

Study results available
· View outcomes & findings →

Summary

The research team hopes to use brain imaging and mental testing to learn more about specific phobias and the treatment of phobia. When given directly prior to therapy sessions, D-cycloserine has been shown to enhance the effects of therapy. This study hopes to identify reasons why D-cycloserine has this effect by measuring brain activity.

Conditions

  • Phobias

Interventions

DRUG

D-cycloserine

D-cycloserine

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • American Psychological Foundation

    collaborator OTHER

  • American Psychological Association

    collaborator UNKNOWN

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Cary Savage, PhD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591825 on ClinicalTrials.gov